Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to test the efficacy and tolerability of a combination treatment
of methotrexate, ibrutinib, and temozolomide (MIT regimen) in treating patients who have
newly-diagnosed primary CNS lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Huiqiang Huang
Collaborators:
Guangdong 999 Brain Hospital Nanfang Hospital of Southern Medical University Xian-Janssen Pharmaceutical Ltd.